Genetic and pharmacologic inhibition of neurotrophic tyrosine receptor kinase 2 (TrkB) consistently reduces glioma responsiveness to glutamate, impairs synaptic connectivity between neurons and glioma cells, and suppresses glioma proliferation driven by neuronal activity [112] (Fig. 3e). This evidence concerns the gene NTRK2 and central nervous system cancer.